If you are not happy with the results below please do another search
Though a Sanofi spokesperson declined to provide details about the operations overhaul, including its timeline, scope and the number of employees that will be terminated, they said that the changes are part of Sanofi’s push to implement “a streamlined strategic sales structure.”
Roche’s subsidiary Genentech has successfully expanded the label of Alecensa to include the adjuvant treatment of anaplastic lymphoma kinase-positive, early-stage non-small cell lung cancer following resection.
Following a months-long safety review, the regulator said it is now requiring black box warnings for all commercially available CAR-T therapies to reflect the risk of secondary malignancies.
The World Health Organization is likely to issue a wider warning about contaminated Johnson and Johnson-made children’s cough syrup found in Nigeria last week, it said in an email.
Drug maker Vifor Pharma has offered to rectify its disparaging campaign against the closest rival to its blockbuster iron deficiency medicine Ferinject, EU antitrust regulators said on Friday, a move that would stave off a potential hefty fine and end an antitrust investigation.
Three core trends emerge as pivotal forces driving the healthcare sector forward: strategic responses to economic uncertainty, the accelerated growth in AI investments, and the groundbreaking advancements in next-generation medications. Together, these trends do not merely represent shifts within the health sector; they signal a critical tipping point, one that demands adaptability, foresight, and an unwavering focus on innovation to navigate the future of health care.
“Over his impressive career, John has successfully scaled technology solutions for the life sciences industry,” said Beth Beghou, CEO of Beghou Consulting. “I know he is as enthusiastic as we are about helping companies develop agile and patient-centric commercialization models.”
Roche subsidiary Genentech on Wednesday released data from the Phase III OCARINA II study, showing that its investigational subcutaneous formulation for Ocrevus (ocrelizumab) strongly reduced relapses and brain lesions in patients with relapsing or primary progressive multiple sclerosis.
Like its branded reference product, Selarsdi is a subcutaneous injection that can be used to treat moderate-to-severe plaque psoriasis and active psoriatic arthritis in pediatric and adult patients. Unlike Stelara, however, Selarsdi is not approved for Crohn’s disease and ulcerative colitis.
The German cartel office has approved a deal by Denmark’s Novo Nordisk (NOVOb.CO) to purchase Cardior Pharmaceuticals, the regulator said in a statement on Thursday.
